Tea Lanisnik Rizner

List of Publications by Year
in descending order

150 papers	4,330 citations	101543 36 h-index	144013 57 g-index
151 all docs	151 docs citations	151 times ranked	4982 citing authors

#	Article	IF	Citations
1	Role of aldoâ€“keto reductase family 1 (AKR1) enzymes in human steroid metabolism. Steroids, 2014, 79, 49-63.	1.8	159
2	AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Molecular and Cellular Endocrinology, 2006, 248, 126-135.	3.2	139
3	Steroid-transforming enzymes in fungi. Journal of Steroid Biochemistry and Molecular Biology, 2012, 129, 79-91.	2.5	133
4	Structureâ€“function of human 3Î±-hydroxysteroid dehydrogenases: genes and proteins. Molecular and Cellular Endocrinology, 2004, 215, 63-72.	3.2	127
5	Human Type 3 3Î±-Hydroxysteroid Dehydrogenase (Aldo-Keto Reductase 1C2) and Androgen Metabolism in Prostate Cells. Endocrinology, 2003, 144, 2922-2932.	2.8	126
6	Estrogen metabolism and action in endometriosis. Molecular and Cellular Endocrinology, 2009, 307, 8-18.	3.2	113
7	Discovery of phosphatidylcholines and sphingomyelins as biomarkers for ovarian endometriosis. Human Reproduction, 2012, 27, 2955-2965.	0.9	108
8	Expression analysis of the genes involved in estradiol and progesterone action in human ovarian endometriosis. Gynecological Endocrinology, 2007, 23, 105-111.	1.7	107
9	The characterization of the human cell line Calu-3 under different culture conditions and its use as an optimized in vitro model to investigate bronchial epithelial function. European Journal of Pharmaceutical Sciences, 2015, 69, 1-9.	4.0	106
10	Disturbed estrogen and progesterone action in ovarian endometriosis. Molecular and Cellular Endocrinology, 2009, 301, 59-64.	3.2	94
11	Evidence for 1,8-dihydroxynaphthalene melanin in three halophilic black yeasts grown under saline and non-saline conditions. FEMS Microbiology Letters, 2004, 232, 203-209.	1.8	81
12	Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer. Molecular and Cellular Endocrinology, 2009, 301, 74-82.	3.2	76
13	The Important Roles of Steroid Sulfatase and Sulfotransferases in Gynecological Diseases. Frontiers in Pharmacology, 2016, 7, 30.	3.5	75
14	A novel 17Î²-hydroxysteroid dehydrogenase in the fungus Cochliobolus lunatus: new insights into the evolution of steroid-hormone signalling. Biochemical Journal, 1999, 337, 425-431.	3.7	68
15	CYP53A15 of Cochliobolus lunatus, a Target for Natural Antifungal Compounds. Journal of Medicinal Chemistry, 2008, 51, 3480-3486.	6.4	68
16	The Characterization of the Human Nasal Epithelial Cell Line RPMI 2650 Under Different Culture Conditions and Their Optimization for an Appropriate in vitro Nasal Model. Pharmaceutical Research, 2015, 32, 665-679.	3.5	63
17	Synthesis and Biological Evaluation of (6- and 7-Phenyl) Coumarin Derivatives as Selective Nonsteroidal Inhibitors of 17Î²-Hydroxysteroid Dehydrogenase Type 1. Journal of Medicinal Chemistry, 2011, 54, 248-261.	6.4	61
18	Estrogen biosynthesis, phase I and phase II metabolism, and action in endometrial cancer. Molecular and Cellular Endocrinology, 2013, 381, 124-139.	3.2	60

#	Article	IF	Citations
19	Melanin biosynthesis in the fungusCurvularia lunata(teleomorph:Cochliobolus lunatus). Canadian Journal of Microbiology, 2003, 49, 110-119.	1.7	59
20	Disturbed expression of phase I and phase II estrogen-metabolizing enzymes in endometrial cancer: Lower levels of CYP1B1 and increased expression of S-COMT. Molecular and Cellular Endocrinology, 2011, 331, 158-167.	3.2	59
21	Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids, 2011, 76, 607-615.	1.8	58
22	Discovery of biomarkers for endometrial cancer: current status and prospects. Expert Review of Molecular Diagnostics, 2016, 16, 1315-1336.	3.1	56
23	Pre-receptor regulation of the androgen receptor. Molecular and Cellular Endocrinology, 2008, 281, 1-8.	3.2	54
24	Altered levels of acylcarnitines, phosphatidylcholines, and sphingomyelins in peritoneal fluid from ovarian endometriosis patients. Journal of Steroid Biochemistry and Molecular Biology, 2016, 159, 60-69.	2.5	52
25	Aldo-Keto Reductases and Cancer Drug Resistance. Pharmacological Reviews, 2021, 73, 1150-1171.	16.0	52
26	Synthesis and Biological Evaluation of Organoruthenium Complexes with Azole Antifungal Agents. First Crystal Structure of a Tioconazole Metal Complex. Organometallics, 2014, 33, 1594-1601.	2.3	51
27	Flavonoids and cinnamic acid derivatives as inhibitors of 17Î²-hydroxysteroid dehydrogenase type 1. Molecular and Cellular Endocrinology, 2009, 301, 229-234.	3.2	48
28	Expression of estrogen and progesterone receptors and estrogen metabolizing enzymes in different breast cancer cell lines. Chemico-Biological Interactions, 2011, 191, 206-216.	4.0	48
29	Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis. Chemico-Biological Interactions, 2011, 191, 217-226.	4.0	46
30	Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: New lead compounds for the development of anticancer agents. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 5170-5175.	2.2	45
31	Cinnamic acids as new inhibitors of 17Î²-hydroxysteroid dehydrogenase type 5 (AKR1C3). Molecular and Cellular Endocrinology, 2006, 248, 233-235.	3.2	45
32	A novel 17Î²-hydroxysteroid dehydrogenase in the fungus Cochliobolus lunatus: new insights into the evolution of steroid-hormone signalling. Biochemical Journal, 1999, 337, 425.	3.7	44
33	Models including plasma levels of sphingomyelins and phosphatidylcholines as diagnostic and prognostic biomarkers of endometrial cancer. Journal of Steroid Biochemistry and Molecular Biology, 2018, 178, 312-321.	2.5	43
34	Noninvasive biomarkers of endometriosis: myth or reality?. Expert Review of Molecular Diagnostics, 2014, 14, 365-385.	3.1	41
35	Flavonoids and cinnamic acid esters as inhibitors of fungal 17Î²-hydroxysteroid dehydrogenase: A synthesis, QSAR and modelling study. Bioorganic and Medicinal Chemistry, 2006, 14, 7404-7418.	3.0	40
36	Purification and characterization of 17Î²-hydroxysteroid dehydrogenase from the filamentous fungus Cochliobolus lunatus. Journal of Steroid Biochemistry and Molecular Biology, 1996, 59, 205-214.	2.5	39

#	Article	IF	Citations
37	Phytoestrogens as inhibitors of the human progesterone metabolizing enzyme AKR1C1. Molecular and Cellular Endocrinology, 2006, 259, 30-42.	3.2	38
38	Panels of Cytokines and Other Secretory Proteins as Potential Biomarkers of Ovarian Endometriosis. Journal of Molecular Diagnostics, 2015, 17, 325-334.	2.8	38
39	Novel estrogen-related genes and potential biomarkers of ovarian endometriosis identified by differential expression analysis. Journal of Steroid Biochemistry and Molecular Biology, 2011, 125, 231-242.	2.5	37
40	Disturbed balance between phase I and II metabolizing enzymes in ovarian endometriosis: A source of excessive hydroxy-estrogens and ROS?. Molecular and Cellular Endocrinology, 2013, 367, 74-84.	3.2	37
41	Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer. Gynecologic Oncology, 2017, 147, 126-132.	1.4	37
42	The endometrial cancer cell lines Ishikawa and HEC-1A, and the control cell line HIEEC, differ in expression of estrogen biosynthetic and metabolic genes, and in androstenedione and estrone-sulfate metabolism. Chemico-Biological Interactions, 2015, 234, 309-319.	4.0	36
43	Rational design of novel mutants of fungal 17Î²-hydroxysteroid dehydrogenase. Journal of Biotechnology, 2007, 129, 123-130.	3.8	35
44	Elevated glycodelin-A concentrations in serum and peritoneal fluid of women with ovarian endometriosis. Gynecological Endocrinology, 2013, 29, 455-459.	1.7	35
45	The Importance of Steroid Uptake and Intracrine Action in Endometrial and Ovarian Cancers. Frontiers in Pharmacology, 2017, 8, 346.	3.5	35
46	Enzymes of the AKR1B and AKR1C Subfamilies and Uterine Diseases. Frontiers in Pharmacology, 2012, 3, 34.	3.5	35
47	Inhibitors of Aldo-Keto Reductases AKR1C1-AKR1C4. Current Medicinal Chemistry, 2011, 18, 2554-2565.	2.4	34
48	Expression analysis of estrogen-metabolizing enzymes in human endometrial cancer. Molecular and Cellular Endocrinology, 2006, 248, 114-117.	3.2	33
49	Altered expression of genes involved in progesterone biosynthesis, metabolism and action in endometrial cancer. Chemico-Biological Interactions, 2013, 202, 210-217.	4.0	33
50	Diagnostic potential of peritoneal fluid biomarkers of endometriosis. Expert Review of Molecular Diagnostics, 2015, 15, 557-580.	3.1	32
51	Steroid hormone signalling system and fungi. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 1995, 112, 637-642.	1.6	31
52	17Î²-Hydroxysteroid Dehydrogenase from Cochliobolus lunatus: Model Structure and Substrate Specificity. Archives of Biochemistry and Biophysics, 2000, 384, 255-262.	3.0	31
53	Expression of AKR1B1, AKR1C3 and other genes of prostaglandin F2Î± biosynthesis and action in ovarian endometriosis tissue and in model cell lines. Chemico-Biological Interactions, 2015, 234, 320-331.	4.0	31
54	Important roles of the AKR1C2 and SRD5A1 enzymes in progesterone metabolism in endometrial cancer model cell lines. Chemico-Biological Interactions, 2015, 234, 297-308.	4.0	31

#	Article	IF	Citations
55	Membrane progesterone receptors Î² and Î³ have potential as prognostic biomarkers of endometrial cancer. Journal of Steroid Biochemistry and Molecular Biology, 2018, 178, 303-311.	2.5	31
56	Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3. Chemico-Biological Interactions, 2011, 191, 227-233.	4.0	30
57	Pyrithione-based ruthenium complexes as inhibitors of aldoâ€"keto reductase 1C enzymes and anticancer agents. Dalton Transactions, 2016, 45, 11791-11800.	3.3	30
58	The Significance of the Sulfatase Pathway for Local Estrogen Formation in Endometrial Cancer. Frontiers in Pharmacology, 2017, 8, 368.	3.5	29
59	Aldo-keto reductase 1C3â€"Assessment as a new target for the treatment of endometriosis. Pharmacological Research, 2020, 152, 104446.	7.1	27
60	Expression of 17Î²-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines. Chemico-Biological Interactions, 2009, 178, 228-233.	4.0	26
61	New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3. European Journal of Medicinal Chemistry, 2009, 44, 2563-2571.	5.5	26
62	Cinnamic acid esters as potent inhibitors of fungal 17Î²-hydroxysteroid dehydrogenaseâ€"â€"a model enzyme of the short-chain dehydrogenase/reductase superfamily. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3933-3936.	2.2	25
63	Characterization of fungal 17Î²-hydroxysteroid dehydrogenases. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2000, 127, 53-63.	1.6	24
64	Expression of 17Î²-hydroxysteroid dehydrogenases in mesophilic and extremophilic yeast. Steroids, 2001, 66, 49-54.	1.8	24
65	Synthesis and structureâ€"activity relationships of 2- and/or 4-halogenated 13<i>Î²</i>- and 13Î±-estrone derivatives as enzyme inhibitors of estrogen biosynthesis. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 1271-1282.	5.2	23
66	Demonstrating suitability of the Caco-2 cell model for BCS-based biowaiver according to the recent FDA and ICH harmonised guidelines. Journal of Pharmacy and Pharmacology, 2019, 71, 1231-1242.	2.4	23
67	Suitability of Isolated Rat Jejunum Model for Demonstration of Complete Absorption in Humans for BCS-Based Biowaiver Request. Journal of Pharmaceutical Sciences, 2012, 101, 1436-1449.	3.3	22
68	Structural basis for inhibition of 17Î²-hydroxysteroid dehydrogenases by phytoestrogens: The case of fungal 17Î²-HSDcl. Journal of Steroid Biochemistry and Molecular Biology, 2017, 171, 80-93.	2.5	21
69	17Î²-hydroxysteroid dehydrogenase from the fungus Cochliobolus lunatus: structural and functional aspects. Chemico-Biological Interactions, 2001, 130-132, 793-803.	4.0	20
70	Selective Inhibitors of Aldo-Keto Reductases AKR1C1 and AKR1C3 Discovered by Virtual Screening of a Fragment Library. Journal of Medicinal Chemistry, 2012, 55, 7417-7424.	6.4	20
71	STAR and AKR1B10 are down-regulated in high-grade endometrial cancer. Journal of Steroid Biochemistry and Molecular Biology, 2017, 171, 43-53.	2.5	20
72	Searching for the physiological function of 17Î²-hydroxysteroid dehydrogenase from the fungus Cochliobolus lunatus: studies of substrate specificity and expression analysis. Molecular and Cellular Endocrinology, 2001, 171, 193-198.	3.2	19

#	Article	IF	Citations
73	Cinnamates and cinnamamides inhibit fungal 17Î²-hydroxysteroid dehydrogenase. Molecular and Cellular Endocrinology, 2006, 248, 239-241.	3.2	19
74	Decreased levels of AKR1B1 and AKR1B10 in cancerous endometrium compared to adjacent non-cancerous tissue. Chemico-Biological Interactions, 2013, 202, 226-233.	4.0	19
75	Significance of individual amino acid residues for coenzyme and substrate specificity of 17Î²-hydroxysteroid dehydrogenase from the fungus Cochliobolus lunatus. Chemico-Biological Interactions, 2003, 143-144, 493-501.	4.0	18
76	Coenzyme specificity in fungal 17Î²-hydroxysteroid dehydrogenase. Molecular and Cellular Endocrinology, 2005, 241, 80-87.	3.2	18
77	Trihydroxynaphthalene reductase of Curvularia lunataâ€"A target for flavonoid action?. Chemico-Biological Interactions, 2009, 178, 259-267.	4.0	18
78	Derivatives of pyrimidine, phthalimide and anthranilic acid as inhibitors of human hydroxysteroid dehydrogenase AKR1C1. Chemico-Biological Interactions, 2009, 178, 158-164.	4.0	17
79	Metabolomics for Diagnosis and Prognosis of Uterine Diseases? A Systematic Review. Journal of Personalized Medicine, 2020, 10, 294.	2.5	17
80	Dimerization and enzymatic activity of fungal 17beta-hydroxysteroid dehydrogenase from the short-chain dehydrogenase/reductase superfamily. BMC Biochemistry, 2005, 6, 28.	4.4	16
81	Phytoestrogens as inhibitors of fungal 17Î²-hydroxysteroid dehydrogenase. Steroids, 2005, 70, 694-703.	1.8	16
82	Ruthenium complexes as inhibitors of the aldoâ€"keto reductases AKR1C1â€"1C3. Chemico-Biological Interactions, 2015, 234, 349-359.	4.0	16
83	Role of human type 3 3Î±-hydroxysteroid dehydrogenase (AKR1C2) in androgen metabolism of prostate cancer cells. Chemico-Biological Interactions, 2003, 143-144, 401-409.	4.0	15
84	Phytoestrogens as inhibitors of fungal 17Î²-hydroxysteroid dehydrogenase. Steroids, 2005, 70, 626-635.	1.8	15
85	Novel Inhibitors of Trihydroxynaphthalene Reductase with Antifungal Activity Identified by Ligand-Based and Structure-Based Virtual Screening. Journal of Chemical Information and Modeling, 2011, 51, 1716-1724.	5.4	15
86	N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldoâ€"keto reductase AKR1C3. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5948-5951.	2.2	15
87	Correlation between erythropoietin receptor(s) and estrogen and progesterone receptor expression in different breast cancer cell lines. International Journal of Molecular Medicine, 2013, 31, 717-725.	4.0	15
88	Proteomic analysis of peritoneal fluid identified COMP and TGFBI as new candidate biomarkers for endometriosis. Scientific Reports, 2021, 11, 20870.	3.3	15
89	Biochemical and biological evaluation of novel potent coumarin inhibitor of 17Î²-HSD type 1. Chemico-Biological Interactions, 2011, 191, 60-65.	4.0	14
90	Expression of human aldo-keto reductase 1C2 in cell lines of peritoneal endometriosis: Potential implications in metabolism of progesterone and dydrogesterone and inhibition by progestins. Journal of Steroid Biochemistry and Molecular Biology, 2012, 130, 16-25.	2.5	13

#	Article	IF	Citations
91	Steroids and microorganisms. Journal of Steroid Biochemistry and Molecular Biology, 2012, 129, 1-3.	2.5	13
92	Phylogenetic Studies, Gene Cluster Analysis, and Enzymatic Reaction Support Anthrahydroquinone Reduction as the Physiological Function of Fungal 17Î²â€Hydroxysteroid Dehydrogenase. ChemBioChem, 2017, 18, 77-80.	2.6	13
93	Discovery of new inhibitors of aldo-keto reductase 1C1 by structure-based virtual screening. Molecular and Cellular Endocrinology, 2009, 301, 245-250.	3.2	12
94	Insights into subtle conformational differences in the substrate-binding loop of fungal 17Î²-hydroxysteroid dehydrogenase: a combined structural and kinetic approach. Biochemical Journal, 2012, 441, 151-160.	3.7	12
95	Effects of progestins on local estradiol biosynthesis and action in the Z-12 endometriotic epithelial cell line. Journal of Steroid Biochemistry and Molecular Biology, 2012, 132, 303-310.	2.5	12
96	Increased levels of biglycan in endometriomas and peritoneal fluid samples from ovarian endometriosis patients. Gynecological Endocrinology, 2014, 30, 520-524.	1.7	12
97	Recommendations for description and validation of antibodies for research use. Journal of Steroid Biochemistry and Molecular Biology, 2016, 156, 40-42.	2.5	12
98	Multiplex analysis of 40 cytokines do not allow separation between endometriosis patients and controls. Scientific Reports, 2019, 9, 16738.	3.3	12
99	Crystallization, X-ray diffraction analysis and phasing of 17Î²-hydroxysteroid dehydrogenase from the fungusCochliobolus lunatus. Acta Crystallographica Section F: Structural Biology Communications, 2005, 61, 1032-1034.	0.7	11
100	Towards the first inhibitors of trihydroxynaphthalene reductase from Curvularia lunata: Synthesis of artificial substrate, homology modelling and initial screening. Bioorganic and Medicinal Chemistry, 2008, 16, 5881-5889.	3.0	11
101	2,3-Diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17Î²-hydroxysteroid dehydrogenase (AKR1C3). European Journal of Medicinal Chemistry, 2013, 62, 89-97.	5.5	10
102	Progestin effects on expression of AKR1C1â€"AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line. Chemico-Biological Interactions, 2013, 202, 218-225.	4.0	10
103	Diagnostic and Therapeutic Values of Angiogenic Factors in Endometrial Cancer. Biomolecules, 2022, 12, 7.	4.0	10
104	His164 regulates accessibility to the active site in fungal 17Î²-hydroxysteroid dehydrogenase. Biochimie, 2007, 89, 63-71.	2.6	9
105	Discovery of highly potent, nonsteroidal 17Î²-hydroxysteroid dehydrogenase type 1 inhibitors by virtual high-throughput screening. Journal of Steroid Biochemistry and Molecular Biology, 2011, 127, 255-261.	2.5	9
106	Combined Liquid Chromatographyâ€"Tandem Mass Spectrometry Analysis of Progesterone Metabolites. PLoS ONE, 2015, 10, e0117984.	2.5	9
107	Different Culture Conditions Affect Drug Transporter Gene Expression, Ultrastructure, and Permeability of Primary Human Nasal Epithelial Cells. Pharmaceutical Research, 2020, 37, 170.	3.5	9
108	AKR1C3 Is Associated with Better Survival of Patients with Endometrial Carcinomas. Journal of Clinical Medicine, 2020, 9, 4105.	2.4	9

#	Article	IF	Citations
109	Teaching the structure of immunoglobulins by molecular visualization and SDSâ€PAGE analysis. Biochemistry and Molecular Biology Education, 2014, 42, 152-159.	1.2	8
110	AKR1B1 and AKR1B10 as Prognostic Biomarkers of Endometrioid Endometrial Carcinomas. Cancers, 2021, 13, 3398.	3.7	8
111	AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer. Cancers, 2022, 14, 809.	3.7	8
112	General toxicity assessment of the novel aldose reductase inhibitor cemtirestat. Interdisciplinary Toxicology, 2019, 12, 120-128.	1.0	7
113	The role of Ala231 and Trp227 in the substrate specificities of fungal 17Î²-hydroxysteroid dehydrogenase and trihydroxynaphthalene reductase: Steroids versus smaller substrates. Journal of Steroid Biochemistry and Molecular Biology, 2012, 129, 92-98.	2.5	6
114	Phospholipase A2 group IIA is elevated in endometriomas but not in peritoneal fluid and serum of ovarian endometriosis patients. Gynecological Endocrinology, 2015, 31, 214-218.	1.7	6
115	It is high time to discontinue use of misidentified and contaminated cells: Guidelines for description and authentication of cell lines. Journal of Steroid Biochemistry and Molecular Biology, 2018, 182, 1-3.	2.5	6
116	Paramount importance of sample quality in pre-clinical and clinical researchâ€"Need for standard operating procedures (SOPs). Journal of Steroid Biochemistry and Molecular Biology, 2019, 186, 1-3.	2.5	6
117	Tie-2, G-CSF, and Leptin as Promising Diagnostic Biomarkers for Endometrial Cancer: A Pilot Study. Journal of Clinical Medicine, 2021, 10, 765.	2.4	6
118	Altered Profile of E1-S Transporters in Endometrial Cancer: Lower Protein Levels of ABCG2 and OSTÎ² and Up-Regulation of SLCO1B3 Expression. International Journal of Molecular Sciences, 2021, 22, 3819.	4.1	6
119	Conformational stability of 17Î²-hydroxysteroid dehydrogenase from the fungus Cochliobolus lunatus. FEBS Journal, 2006, 273, 3927-3937.	4.7	5
120	Two homologous fungal carbonyl reductases with different substrate specificities. Chemico-Biological Interactions, 2009, 178, 295-302.	4.0	5
121	Data on expression of genes involved in estrogen and progesterone action, inflammation and differentiation according to demographic, histopathological and clinical characteristics of endometrial cancer patients. Data in Brief, 2017, 12, 632-643.	1.0	5
122	Models including serum CA-125, BMI, cyst pathology, dysmenorrhea or dyspareunia for diagnosis of endometriosis. Biomarkers in Medicine, 2018, 12, 737-747.	1.4	5
123	Metabolism of Estrogens: Turnover Differs between Platinum-Sensitive and -Resistant High-Grade Serous Ovarian Cancer Cells. Cancers, 2020, 12, 279.	3.7	5
124	Heterocyclic androstane and estrane d-ring modified steroids: Microwave-assisted synthesis, steroid-converting enzyme inhibition, apoptosis induction, and effects on genes encoding estrogen inactivating enzymes. Journal of Steroid Biochemistry and Molecular Biology, 2021, 214, 105997.	2.5	5
125	Estrogens and the SchrÃ¶dingerâ€™s Cat in the Ovarian Tumor Microenvironment. Cancers, 2021, 13, 5011.	3.7	5
126	In the Model Cell Lines of Moderately and Poorly Differentiated Endometrial Carcinoma, Estrogens Can Be Formed via the Sulfatase Pathway. Frontiers in Molecular Biosciences, 2021, 8, 743403.	3.5	5

#	Article	IF	Citations
127	Model Cell Lines and Tissues of Different HGSOC Subtypes Differ in Local Estrogen Biosynthesis. Cancers, 2022, 14, 2583.	3.7	5
128	New enzymatic assay for the AKR1C enzymes. Chemico-Biological Interactions, 2013, 202, 204-209.	4.0	4
129	<i>N</i>â€Phenylâ€1,2,3,4â€tetrahydroisoquinoline: An Alternative Scaffold for the Design of 17Î²â€Hydroxysteroid Dehydrogenase 1 Inhibitors. ChemMedChem, 2021, 16, 259-291.	3.2	4
130	New inhibitors of fungal 17Î²-hydroxysteroid dehydrogenase based on the [1,5]-benzodiazepine scaffold. Journal of Enzyme Inhibition and Medicinal Chemistry, 2007, 22, 29-36.	5.2	3
131	Simultaneous binding of coenzyme and two ligand molecules into the active site of fungal trihydroxynaphthalene reductase. Chemico-Biological Interactions, 2009, 178, 268-273.	4.0	3
132	Mutations that affect coenzyme binding and dimer formation of fungal 17Î²-hydroxysteroid dehydrogenase. Molecular and Cellular Endocrinology, 2009, 301, 47-50.	3.2	3
133	Synthesis and evaluation of AKR1C inhibitory properties of A-ring halogenated oestrone derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 1499-1507.	5.2	3
134	Design and synthesis of substrate mimetics based on an indole scaffold: potential inhibitors of 17Î²-HSD type 1. Hormone Molecular Biology and Clinical Investigation, 2011, 6, 201-209.	0.7	2
135	Biomarkers of endometriosis: How far have we come and where are we going?. ZdravniÅ¡ki Vestnik, 2021, 90, 256-265.	0.1	2
136	Antibody Arrays Identified Cycle-Dependent Plasma Biomarker Candidates of Peritoneal Endometriosis. Journal of Personalized Medicine, 2022, 12, 852.	2.5	2
137	Detection of Aristaless-related homeobox protein in ovarian sex cord-stromal tumors. Experimental and Molecular Pathology, 2018, 104, 38-44.	2.1	1
138	Editorial: Relevance of Steroid Biosynthesis, Metabolism and Transport in Pathophysiology and Drug Discovery. Frontiers in Pharmacology, 2019, 10, 245.	3.5	1
139	Physiological Concentrations of Cimicifuga racemosa Extract Do Not Affect Expression of Genes Involved in Estrogen Biosynthesis and Action in Endometrial and Ovarian Cell Lines. Biomolecules, 2022, 12, 545.	4.0	1
140	Preparation of Recombinant Human Hydroxysteroid Dehydrogenases and Study of their Inhibitors. Scientia Pharmaceutica, 2010, 78, 592-592.	2.0	0
141	Introduction. Chemico-Biological Interactions, 2013, 202, 1.	4.0	0
142	Abstract 464: BioEndoCar: in search of new Biomarkers for Diagnosis and Prognosis of Endometrial Carcinoma. , 2021, , .		0
143	412â€…BioEndoCar: omics approaches for diagnosis and prognosis of endometrial cancer. , 2021, , .		0
144	783â€…AKR1C3 â€“ a potential prognostic biomarker for patients with endometrial carcinomas. , 2021, , .		0

#	Article	IF	Citations
145	622â€…The role of angiogenic factors in endometrial cancer. , 2021, , .		0
146	Medikamentozno zdravljenje endometrioze: pregled stanja in nove moÅ¾nosti zdravljenja. ZdravniÅ¡ki Vestnik, 2016, 85, .	0.1	0
147	EP555â€…Biomarkers for diagnosis and prognosis of endometrial carcinoma: BioEndoCar. , 2019, , .		0
148	EP556â€…Decreased s-Tie2 plasma concentration in patients with endometrioid endometrial cancer. , 2019, , .		0
149	EP554â€…The effects ofCimicifuga racemosaextract on endometrial and ovarian cancer cell lines. , 2019, , .		0
150	P82â€…Decreased expression ofABCG2andSLC51Bin endometrial cancer. , 2019, , .		0